BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacol Rev 2012;64:389-420. [DOI: 10.1124/pr.111.005546] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Winrow CJ, Renger JJ. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. Br J Pharmacol 2014;171:283-93. [PMID: 23731216 DOI: 10.1111/bph.12261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 88] [Article Influence: 10.8] [Reference Citation Analysis]
2 Boss C, Roch C. Orexin research: patent news from 2016. Expert Opinion on Therapeutic Patents 2017;27:1123-33. [DOI: 10.1080/13543776.2017.1344221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Mousavi Y, Azizi H, Mirnajafi-zadeh J, Javan M, Semnanian S. Blockade of orexin type-1 receptors in locus coeruleus nucleus attenuates the development of morphine dependency in rats. Neuroscience Letters 2014;578:90-4. [DOI: 10.1016/j.neulet.2014.06.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
4 Tsuneki H, Wada T, Sasaoka T. Chronopathophysiological implications of orexin in sleep disturbances and lifestyle-related disorders. Pharmacology & Therapeutics 2018;186:25-44. [DOI: 10.1016/j.pharmthera.2017.12.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
5 Futamura A, Nozawa D, Araki Y, Tamura Y, Tokura S, Kawamoto H, Tokumaru Y, Kakihara S, Aoki T, Ohtake N. Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide. Bioorganic & Medicinal Chemistry 2017;25:5203-15. [DOI: 10.1016/j.bmc.2017.07.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Hoffmann J, Supronsinchai W, Akerman S, Andreou AP, Winrow CJ, Renger J, Hargreaves R, Goadsby PJ. Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease 2015;74:137-43. [DOI: 10.1016/j.nbd.2014.10.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 7.1] [Reference Citation Analysis]
7 Perrey DA, German NA, Gilmour BP, Li JX, Harris DL, Thomas BF, Zhang Y. Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor. J Med Chem 2013;56:6901-16. [PMID: 23941044 DOI: 10.1021/jm400720h] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
8 Ezzatpanah S, Babapour V, Haghparast A. Differential contribution of orexin receptors within the ventral tegmental area to modulation of persistent inflammatory pain. Eur J Pain 2016;20:1090-101. [DOI: 10.1002/ejp.833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
9 Stump CA, Cooke AJ, Bruno J, Cabalu TD, Gotter AL, Harell CM, Kuduk SD, Mcdonald TP, O’brien J, Renger JJ, Williams PD, Winrow CJ, Coleman PJ. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Bioorganic & Medicinal Chemistry Letters 2016;26:5809-14. [DOI: 10.1016/j.bmcl.2016.10.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
10 Lopez MF, Moorman DE, Aston-Jones G, Becker HC. The highly selective orexin/hypocretin 1 receptor antagonist GSK1059865 potently reduces ethanol drinking in ethanol dependent mice. Brain Res 2016;1636:74-80. [PMID: 26851547 DOI: 10.1016/j.brainres.2016.01.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
11 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
13 Dugovic C, Shelton JE, Yun S, Bonaventure P, Shireman BT, Lovenberg TW. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Front Neurosci 2014;8:28. [PMID: 24592208 DOI: 10.3389/fnins.2014.00028] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
14 Asadi S, Roohbakhsh A, Shamsizadeh A, Fereidoni M, Kordijaz E, Moghimi A. The effect of intracerebroventricular administration of orexin receptor type 2 antagonist on pentylenetetrazol-induced kindled seizures and anxiety in rats. BMC Neurosci 2018;19:49. [PMID: 30103703 DOI: 10.1186/s12868-018-0445-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Grafe LA, Eacret D, Luz S, Gotter AL, Renger JJ, Winrow CJ, Bhatnagar S. Orexin 2 receptor regulation of the hypothalamic-pituitary-adrenal (HPA) response to acute and repeated stress. Neuroscience 2017;348:313-23. [PMID: 28257896 DOI: 10.1016/j.neuroscience.2017.02.038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
16 Johnson PL, Federici LM, Fitz SD, Renger JJ, Shireman B, Winrow CJ, Bonaventure P, Shekhar A. OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES. Depress Anxiety 2015;32:671-83. [PMID: 26332431 DOI: 10.1002/da.22403] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
17 Deats SP, Adidharma W, Lonstein JS, Yan L. Attenuated orexinergic signaling underlies depression-like responses induced by daytime light deficiency. Neuroscience 2014;272:252-60. [PMID: 24813431 DOI: 10.1016/j.neuroscience.2014.04.069] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
18 Gotter AL, Winrow CJ, Brunner J, Garson SL, Fox SV, Binns J, Harrell CM, Cui D, Yee KL, Stiteler M, Stevens J, Savitz A, Tannenbaum PL, Tye SJ, McDonald T, Yao L, Kuduk SD, Uslaner J, Coleman PJ, Renger JJ. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 2013;14:90. [PMID: 23981345 DOI: 10.1186/1471-2202-14-90] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
19 Burish MJ, Winsvold BS, Miao H. The current state of cluster headache genetics. Headache 2021;61:990-1. [PMID: 34363404 DOI: 10.1111/head.14166] [Reference Citation Analysis]
20 Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2017;20:613-8. [PMID: 28582570 DOI: 10.1093/ijnp/pyx033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
21 Sun M, Wang W, Li Q, Yuan T, Weng W. Orexin A may suppress inflammatory response in fibroblast-like synoviocytes. Biomedicine & Pharmacotherapy 2018;107:763-8. [DOI: 10.1016/j.biopha.2018.07.159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
22 Ramirez AD, Gotter AL, Fox SV, Tannenbaum PL, Yao L, Tye SJ, McDonald T, Brunner J, Garson SL, Reiss DR, Kuduk SD, Coleman PJ, Uslaner JM, Hodgson R, Browne SE, Renger JJ, Winrow CJ. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators. Front Neurosci 2013;7:254. [PMID: 24399926 DOI: 10.3389/fnins.2013.00254] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
23 Tabikh M, Chahla C, Okdeh N, Kovacic H, Sabatier J, Fajloun Z. Parkinson disease: protective role and function of neuropeptides. Peptides 2021. [DOI: 10.1016/j.peptides.2021.170713] [Reference Citation Analysis]
24 Born S, Gauvin DV, Mukherjee S, Briscoe R. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 2017;86:181-92. [PMID: 28279667 DOI: 10.1016/j.yrtph.2017.03.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
25 Herrero Babiloni A, De Koninck BP, Beetz G, De Beaumont L, Martel MO, Lavigne GJ. Sleep and pain: recent insights, mechanisms, and future directions in the investigation of this relationship. J Neural Transm 2020;127:647-60. [DOI: 10.1007/s00702-019-02067-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
26 Yazdi F, Jahangirvand M, Ezzatpanah S, Haghparast A. Role of orexin-2 receptors in the nucleus accumbens in antinociception induced by carbachol stimulation of the lateral hypothalamus in formalin test. Behav Pharmacol 2016;27:431-8. [PMID: 26871404 DOI: 10.1097/FBP.0000000000000216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Fonseca EM, Janes TA, Fournier S, Gargaglioni LH, Kinkead R. Orexin-A inhibits fictive air breathing responses to respiratory stimuli in the bullfrog tadpole (Lithobates catesbeianus). J Exp Biol 2021;224:jeb240804. [PMID: 33914034 DOI: 10.1242/jeb.240804] [Reference Citation Analysis]
28 Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD. Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. J Psychopharmacol 2015;29:1159-69. [PMID: 26464455 DOI: 10.1177/0269881115609015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
29 Bertels Z, Pradhan AAA. Emerging Treatment Targets for Migraine and Other Headaches. Headache 2019;59 Suppl 2:50-65. [PMID: 31291018 DOI: 10.1111/head.13585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
30 Messina A, De Fusco C, Monda V, Esposito M, Moscatelli F, Valenzano A, Carotenuto M, Viggiano E, Chieffi S, De Luca V, Cibelli G, Monda M, Messina G. Role of the Orexin System on the Hypothalamus-Pituitary-Thyroid Axis. Front Neural Circuits 2016;10:66. [PMID: 27610076 DOI: 10.3389/fncir.2016.00066] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
31 Wardach J, Wagner M, Jeong Y, Holden JE. Lateral Hypothalamic Stimulation Reduces Hyperalgesia Through Spinally Descending Orexin-A Neurons in Neuropathic Pain. West J Nurs Res 2016;38:292-307. [PMID: 26475681 DOI: 10.1177/0193945915610083] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
32 Martin EJ, Hernandez ME, Hayward LF. Blockade of orexin receptors attenuates the cardiovascular response to air-jet stress in spontaneously hypertensive rats. Auton Neurosci 2016;201:8-16. [PMID: 27591948 DOI: 10.1016/j.autneu.2016.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
33 Kordi Jaz E, Moghimi A, Fereidoni M, Asadi S, Shamsizadeh A, Roohbakhsh A. SB-334867, an orexin receptor 1 antagonist, decreased seizure and anxiety in pentylenetetrazol-kindled rats. Fundam Clin Pharmacol 2017;31:201-7. [DOI: 10.1111/fcp.12249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
34 Du D, Zhang Y, Zhu C, Chen H, Sun J. Metabolic Regulation of Hypoxia-Inducible Factors in Hypothalamus. Front Endocrinol (Lausanne) 2021;12:650284. [PMID: 33763034 DOI: 10.3389/fendo.2021.650284] [Reference Citation Analysis]
35 Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol 2016;19:pyw022. [PMID: 26979830 DOI: 10.1093/ijnp/pyw022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
36 Kuduk SD, Winrow CJ, Coleman PJ. Orexin Receptor Antagonists in Development for Insomnia and CNS Disorders. Elsevier; 2013. pp. 73-87. [DOI: 10.1016/b978-0-12-417150-3.00006-5] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
37 Doghramji PP. Integrating Modern Concepts of Insomnia and its Contemporary Treatment into Primary Care. Postgraduate Medicine 2015;126:82-101. [DOI: 10.3810/pgm.2014.09.2802] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
38 Shaw JK, Ferris MJ, Locke JL, Brodnik ZD, Jones SR, España RA. Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine. Addict Biol 2017;22:1695-705. [PMID: 27480648 DOI: 10.1111/adb.12432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
39 Steiner MA, Sciarretta C, Pasquali A, Jenck F. The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol 2013;4:165. [PMID: 24416020 DOI: 10.3389/fphar.2013.00165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
40 Steiner MA, Gatfield J, Brisbare-Roch C, Dietrich H, Treiber A, Jenck F, Boss C. Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 2013;8:898-903. [PMID: 23589487 DOI: 10.1002/cmdc.201300003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
41 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
42 Carrive P. Orexin, Stress and Central Cardiovascular Control. A Link with Hypertension? Neurosci Biobehav Rev 2017;74:376-92. [PMID: 27477446 DOI: 10.1016/j.neubiorev.2016.06.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
43 Kumar A, Chanana P, Choudhary S. Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 2016;68:231-42. [DOI: 10.1016/j.pharep.2015.09.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
44 Mohammad Ahmadi Soleimani S, Azizi H, Mirnajafi-zadeh J, Semnanian S. Orexin type 1 receptor antagonism in rat locus coeruleus prevents the analgesic effect of intra-LC met-enkephalin microinjection. Pharmacology Biochemistry and Behavior 2015;136:102-6. [DOI: 10.1016/j.pbb.2015.07.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
45 Goadsby PJ. Putting migraine to sleep: Rexants as a preventive strategy. Cephalalgia 2015;35:377-8. [DOI: 10.1177/0333102414566196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
46 Roecker AJ, Mercer SP, Schreier JD, Cox CD, Fraley ME, Steen JT, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of 5''-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2':5',3''-terpyridine-3'-carboxamide (MK-1064): a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem 2014;9:311-22. [PMID: 24376006 DOI: 10.1002/cmdc.201300447] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
47 Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, Menezes MM, Schober DA, Rorick-Kehn LM. LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. Front Neurosci 2014;8:5. [PMID: 24478625 DOI: 10.3389/fnins.2014.00005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
48 Deats SP, Adidharma W, Yan L. Hypothalamic dopaminergic neurons in an animal model of seasonal affective disorder. Neurosci Lett 2015;602:17-21. [PMID: 26116821 DOI: 10.1016/j.neulet.2015.06.038] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
49 Perrey DA, Decker AM, Zhang Y. Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability. ACS Chem Neurosci 2018;9:587-602. [PMID: 29129052 DOI: 10.1021/acschemneuro.7b00402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
50 Treu SP, Plante DT. Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis. Sleep Med 2021;85:230-8. [PMID: 34364094 DOI: 10.1016/j.sleep.2021.07.007] [Reference Citation Analysis]
51 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
52 Brodnik ZD, Alonso IP, Xu W, Zhang Y, Kortagere S, España RA. Hypocretin receptor 1 involvement in cocaine-associated behavior: Therapeutic potential and novel mechanistic insights. Brain Res 2020;1731:145894. [PMID: 30071195 DOI: 10.1016/j.brainres.2018.07.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
53 Cai Z, Liu H, Wang L, Li X, Bai L, Gan X, Li L, Han C. Molecular Evolutionary Analysis of the HCRTR Gene Family in Vertebrates. Biomed Res Int 2018;2018:8120263. [PMID: 29967787 DOI: 10.1155/2018/8120263] [Reference Citation Analysis]
54 Wu F, Song G, de Graaf C, Stevens RC. Structure and Function of Peptide-Binding G Protein-Coupled Receptors. J Mol Biol 2017;429:2726-45. [PMID: 28705763 DOI: 10.1016/j.jmb.2017.06.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
55 Beig MI, Dampney BW, Carrive P. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Neuropharmacology 2015;89:146-56. [PMID: 25239810 DOI: 10.1016/j.neuropharm.2014.09.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
56 Grafe LA, Bhatnagar S. Orexins and stress. Front Neuroendocrinol 2018;51:132-45. [PMID: 29932958 DOI: 10.1016/j.yfrne.2018.06.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 8.5] [Reference Citation Analysis]
57 Sifferlen T, Boller A, Chardonneau A, Cottreel E, Gatfield J, Treiber A, Roch C, Jenck F, Aissaoui H, Williams JT, Brotschi C, Heidmann B, Siegrist R, Boss C. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2. Bioorganic & Medicinal Chemistry Letters 2015;25:1884-91. [DOI: 10.1016/j.bmcl.2015.03.035] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
58 Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, Stump C, Tannenbaum PL, Williams PD, Winrow CJ, Coleman PJ. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters 2015;25:444-50. [DOI: 10.1016/j.bmcl.2014.12.056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
59 Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Garson SL, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties. Bioorg Med Chem Lett 2015;25:2488-92. [PMID: 25981685 DOI: 10.1016/j.bmcl.2015.04.066] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
60 Carrive P. Orexin, orexin receptor antagonists and central cardiovascular control. Front Neurosci 2013;7:257. [PMID: 24415993 DOI: 10.3389/fnins.2013.00257] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
61 Cady RJ, Denson JE, Sullivan LQ, Durham PL. Dual orexin receptor antagonist 12 inhibits expression of proteins in neurons and glia implicated in peripheral and central sensitization. Neuroscience 2014;269:79-92. [PMID: 24685439 DOI: 10.1016/j.neuroscience.2014.03.043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
62 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
63 Levy KA, Brodnik ZD, Shaw JK, Perrey DA, Zhang Y, España RA. Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling. Psychopharmacology (Berl) 2017;234:2761-76. [PMID: 28667509 DOI: 10.1007/s00213-017-4673-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
64 Machaalani R, Hunt NJ, Waters KA. Effects of changes in energy homeostasis and exposure of noxious insults on the expression of orexin (hypocretin) and its receptors in the brain. Brain Res 2013;1526:102-22. [PMID: 23830852 DOI: 10.1016/j.brainres.2013.06.035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
65 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
66 Beig MI, Horiuchi J, Dampney RA, Carrive P. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus. Clin Exp Pharmacol Physiol 2015;42:1059-67. [DOI: 10.1111/1440-1681.12461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
67 Mcdonald T, Liang HA, Sanoja R, Gotter AL, Kuduk SD, Coleman PJ, Smith KM, Winrow CJ, Renger JJ. Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. Journal of Neurogenetics 2016;30:32-41. [DOI: 10.3109/01677063.2016.1171862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Emam AH, Hajesfandiari N, Shahidi S, Komaki A, Ganji M, Sarihi A. Modulation of nociception by medial pre-optic area orexin a receptors and its relation with morphine in male rats. Brain Res Bull 2016;127:141-7. [PMID: 27641968 DOI: 10.1016/j.brainresbull.2016.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Boutrel B, Steiner N, Halfon O. The hypocretins and the reward function: what have we learned so far? Front Behav Neurosci 2013;7:59. [PMID: 23781178 DOI: 10.3389/fnbeh.2013.00059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
70 Haghparast A, Shafiei I, Alizadeh A, Ezzatpanah S, Haghparast A. Blockade of the orexin receptors in the CA1 region of hippocampus decreased the lateral hypothalamic-induced antinociceptive responses in the model of orofacial formalin test in the rats. Peptides 2018;99:217-22. [DOI: 10.1016/j.peptides.2017.10.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
71 Fujisawa S, Komatsubara M, Ogura-Ochi K, Tsukamoto-Yamauchi N, Toma K, Inagaki K, Wada J, Otsuka F. Orexin A modulates prolactin production by regulating BMP-4 activity in rat pituitary lactotorope cells. Peptides 2019;113:35-40. [PMID: 30721716 DOI: 10.1016/j.peptides.2019.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
72 González MMC. Dim Light at Night and Constant Darkness: Two Frequently Used Lighting Conditions That Jeopardize the Health and Well-being of Laboratory Rodents. Front Neurol 2018;9:609. [PMID: 30116218 DOI: 10.3389/fneur.2018.00609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
73 Roecker AJ, Reger TS, Mattern MC, Mercer SP, Bergman JM, Schreier JD, Cube RV, Cox CD, Li D, Lemaire W, Bruno JG, Harrell CM, Garson SL, Gotter AL, Fox SV, Stevens J, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Stellabott J, Hartman GD, Young SD, Winrow CJ, Renger JJ, Coleman PJ. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett 2014;24:4884-90. [PMID: 25248679 DOI: 10.1016/j.bmcl.2014.08.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
74 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
75 Barson JR. Orexin/hypocretin and dysregulated eating: Promotion of foraging behavior. Brain Res 2020;1731:145915. [PMID: 30125533 DOI: 10.1016/j.brainres.2018.08.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
76 Yee KL, Mccrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig 2018;38:631-8. [DOI: 10.1007/s40261-018-0650-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
77 Volta M, Lavdas AA, Obergasteiger J, Überbacher C, Picard A, Pramstaller PP, Hicks AA, Corti C. Elevated levels of alpha-synuclein blunt cellular signal transduction downstream of Gq protein-coupled receptors. Cell Signal 2017;30:82-91. [PMID: 27871937 DOI: 10.1016/j.cellsig.2016.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Kuduk SD, Skudlarek JW, Di Marco CN, Bruno JG, Pausch MA, O’brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ. Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant. Bioorganic & Medicinal Chemistry Letters 2014;24:1784-9. [DOI: 10.1016/j.bmcl.2014.02.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
79 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
80 Jacobson LH, Callander GE, Hoyer D. Suvorexant for the treatment of insomnia. Expert Rev Clin Pharmacol 2014;7:711-30. [PMID: 25318834 DOI: 10.1586/17512433.2014.966813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
81 Brodnik ZD, Bernstein DL, Prince CD, España RA. Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behav Brain Res 2015;291:377-84. [PMID: 26049058 DOI: 10.1016/j.bbr.2015.05.051] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
82 Tannenbaum PL, Stevens J, Binns J, Savitz AT, Garson SL, Fox SV, Coleman P, Kuduk SD, Gotter AL, Marino M, Tye SJ, Uslaner JM, Winrow CJ, Renger JJ. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Front Behav Neurosci 2014;8:182. [PMID: 24904334 DOI: 10.3389/fnbeh.2014.00182] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
83 Matzeu A, Zamora-Martinez ER, Martin-Fardon R. The paraventricular nucleus of the thalamus is recruited by both natural rewards and drugs of abuse: recent evidence of a pivotal role for orexin/hypocretin signaling in this thalamic nucleus in drug-seeking behavior. Front Behav Neurosci 2014;8:117. [PMID: 24765071 DOI: 10.3389/fnbeh.2014.00117] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
84 Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 2013;170:1459-581. [PMID: 24517644 DOI: 10.1111/bph.12445] [Cited by in Crossref: 504] [Cited by in F6Publishing: 489] [Article Influence: 63.0] [Reference Citation Analysis]
85 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
86 Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clin Auton Res 2018;28:545-55. [DOI: 10.1007/s10286-017-0473-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
87 Lei K, Kwok C, Hopf FW. Nucleus accumbens shell Orexin-1 receptors are not needed for single-bottle limited daily access alcohol intake in C57BL/6 mice. Alcohol 2020;89:139-46. [PMID: 32987129 DOI: 10.1016/j.alcohol.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
89 Fox SV, Gotter AL, Tye SJ, Garson SL, Savitz AT, Uslaner JM, Brunner JI, Tannenbaum PL, McDonald TP, Hodgson R, Yao L, Bowlby MR, Kuduk SD, Coleman PJ, Hargreaves R, Winrow CJ, Renger JJ. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats. Neuropsychopharmacology 2013;38:2401-8. [PMID: 23722242 DOI: 10.1038/npp.2013.139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
90 Roecker AJ, Mercer SP, Harrell CM, Garson SL, Fox SV, Gotter AL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters 2014;24:2079-85. [DOI: 10.1016/j.bmcl.2014.03.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
91 Bernstein DL, Badve PS, Barson JR, Bass CE, España RA. Hypocretin receptor 1 knockdown in the ventral tegmental area attenuates mesolimbic dopamine signaling and reduces motivation for cocaine. Addict Biol 2018;23:1032-45. [PMID: 28971565 DOI: 10.1111/adb.12553] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
92 Calva CB, Fayyaz H, Fadel JR. Increased acetylcholine and glutamate efflux in the prefrontal cortex following intranasal orexin-A (hypocretin-1). J Neurochem 2018;145:232-44. [PMID: 29250792 DOI: 10.1111/jnc.14279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
93 Chen Q, de Lecea L, Hu Z, Gao D. The hypocretin/orexin system: an increasingly important role in neuropsychiatry. Med Res Rev 2015;35:152-97. [PMID: 25044006 DOI: 10.1002/med.21326] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
94 Nicole P, Couvineau P, Jamin N, Voisin T, Couvineau A. Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol 2015;172:5211-23. [PMID: 26282891 DOI: 10.1111/bph.13287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
95 Gotter AL, Roecker AJ, Hargreaves R, Coleman PJ, Winrow CJ, Renger JJ. Orexin receptors as therapeutic drug targets. Prog Brain Res 2012;198:163-88. [PMID: 22813974 DOI: 10.1016/B978-0-444-59489-1.00010-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 24] [Article Influence: 7.1] [Reference Citation Analysis]
96 Bigal ME, Hargreaves RJ. Why does sleep stop migraine? Curr Pain Headache Rep 2013;17:369. [PMID: 24037443 DOI: 10.1007/s11916-013-0369-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
97 Hoyer D, Jacobson LH. Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand? Neuropeptides 2013;47:477-88. [DOI: 10.1016/j.npep.2013.10.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 7.4] [Reference Citation Analysis]
98 Du MK, Hunt NJ, Waters KA, Machaalani R. Cumulative effects of repetitive intermittent hypercapnic hypoxia on orexin in the developing piglet hypothalamus. Int J Dev Neurosci 2016;48:1-8. [PMID: 26548856 DOI: 10.1016/j.ijdevneu.2015.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
99 Wang Q, Cao F, Wu Y. Orexinergic System in Neurodegenerative Diseases. Front Aging Neurosci 2021;13:713201. [PMID: 34483883 DOI: 10.3389/fnagi.2021.713201] [Reference Citation Analysis]
100 Joseph Herring W, Ge JY, Jackson S, Assaid C, Connor KM, Michelson D. Orexin Receptor Antagonism in Painful Diabetic Neuropathy: A Phase 2 Trial With Filorexant. Clin J Pain 2018;34:37-43. [PMID: 28448426 DOI: 10.1097/AJP.0000000000000503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Lebold TP, Bonaventure P, Shireman BT. Selective orexin receptor antagonists. Bioorg Med Chem Lett 2013;23:4761-9. [PMID: 23891187 DOI: 10.1016/j.bmcl.2013.06.057] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
102 Carrive P, Kuwaki T. Orexin and Central Modulation of Cardiovascular and Respiratory Function. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 157-96. [DOI: 10.1007/7854_2016_46] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
103 Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters 2015;25:4992-9. [DOI: 10.1016/j.bmcl.2014.12.081] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
104 Yardley DA. Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press) 2016;8:73-82. [PMID: 27217795 DOI: 10.2147/BCTT.S97963] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
105 Song J, Kim E, Kim CH, Song HT, Lee JE. The role of orexin in post-stroke inflammation, cognitive decline, and depression. Mol Brain 2015;8:16. [PMID: 25884812 DOI: 10.1186/s13041-015-0106-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
106 Trofimova I, Robbins TW. Temperament and arousal systems: A new synthesis of differential psychology and functional neurochemistry. Neurosci Biobehav Rev 2016;64:382-402. [PMID: 26969100 DOI: 10.1016/j.neubiorev.2016.03.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
107 Adeghate E, Lotfy M, D'Souza C, Alseiari SM, Alsaadi AA, Qahtan SA. Hypocretin/orexin modulates body weight and the metabolism of glucose and insulin. Diabetes Metab Res Rev 2020;36:e3229. [PMID: 31655012 DOI: 10.1002/dmrr.3229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
108 Skudlarek JW, Dimarco CN, Babaoglu K, Roecker AJ, Bruno JG, Pausch MA, O'brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Wuelfing WP, Garson SL, Fox SV, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Kuduk SD, Coleman PJ. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2017;27:1364-70. [DOI: 10.1016/j.bmcl.2017.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
109 Wei H, Guan YD, Zhang LX, Liu S, Lu AP, Cheng Y, Cao DS. A combinatorial target screening strategy for deorphaning macromolecular targets of natural product. Eur J Med Chem 2020;204:112644. [PMID: 32738412 DOI: 10.1016/j.ejmech.2020.112644] [Reference Citation Analysis]
110 Ericson MD, Haskell-Luevano C. A Review of Single-Nucleotide Polymorphisms in Orexigenic Neuropeptides Targeting G Protein-Coupled Receptors. ACS Chem Neurosci 2018;9:1235-46. [PMID: 29714060 DOI: 10.1021/acschemneuro.8b00151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]